Ahsan Farooq, MD
Endocrinology, Diabetes & Metabolism · Montgomery, ALNPI 1558712596
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 262 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 18.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,507 and has fallen 67.7% since, to $486 in 2025. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in AL, where the typical reported total is $6,650.
Across 262 payments — averaging $17.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$817
- Abbott$564
- Dexcom, Inc.$468
- Lilly USA, LLC$340
- Boehringer Ingelheim$228
- Sanofi-aventis U.S. LLC$227
- plus $2K from 24 others
What the payments were for
- Food & beverage$4,44599%
- Education$521%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 46 | $817 |
| Abbott | 36 | $564 |
| Dexcom, Inc. | 32 | $468 |
| Lilly USA, LLC | 24 | $340 |
| Boehringer Ingelheim | 14 | $228 |
| Sanofi-aventis U.S. LLC | 12 | $227 |
| Medtronic | 8 | $197 |
| Corcept Therapeutics | 9 | $164 |
| AbbVie | 9 | $152 |
| BETA Bionics, Inc. | 7 | $138 |
| Amgen | 8 | $136 |
| Lifescan, Inc. | 7 | $136 |
| Mannkind Corporation | 7 | $134 |
| Insulet Corporation | 5 | $100 |
| Xeris Pharmaceuticals, Inc. | 4 | $84 |
| Novartis | 5 | $80 |
| Pfizer | 4 | $63 |
| IBSA Pharma Inc. | 3 | $58 |
| Tandem Diabetes Care, Inc. | 3 | $57 |
| Ultragenyx Pharmaceutical Inc. | 2 | $54 |
| AstraZeneca(2 entities) | 3 | $51 |
| Amneal Pharmaceuticals LLC | 3 | $49 |
| Kyowa Kirin, Inc. | 2 | $40 |
| Amarin Pharma, Inc. | 2 | $37 |
| Ascendis Pharma Endocrinology Inc | 1 | $28 |
| Merck | 2 | $27 |
| Recordati_rare_diseases_inc. | 1 | $24 |
| Amryt Pharma Holdings Ltd | 1 | $19 |
| Bayer | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
How this compares
$4,497 in reported general payments places this provider in the 35th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
See all endocrinology, diabetes & metabolism providers in Alabama →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 288 | $351,073 |
| MounjaroTirzepatide | 278 | $329,395 |
| JardianceEmpagliflozin | 153 | $165,766 |
| Tresiba Flextouch U-200Insulin Degludec | 115 | $127,714 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 120 | $119,582 |
| JanuviaSitagliptin Phosphate | 87 | $65,837 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 105 | $58,982 |
| TrulicityDulaglutide | 34 | $53,623 |
| Tresiba Flextouch U-100Insulin Degludec | 79 | $52,160 |
| Humalog Kwikpen U-100Insulin Lispro | 162 | $45,753 |
| FarxigaDapagliflozin Propanediol | 35 | $42,548 |
| RybelsusSemaglutide | 18 | $27,943 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 173 | $21,634 |
| Novolog FlexpenInsulin Aspart | 83 | $21,318 |
| TradjentaLinagliptin | 20 | $20,147 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $340 | $393,360355 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $817 | $386,489327 claims |
| Boehringer IngelheimJardiance, Tradjenta | $228 | $185,912173 claims |
| MerckJanuvia | $27 | $65,83787 claims |
| AstraZenecaFarxiga | $51 | $42,54835 claims |
| Mannkind CorporationAfrezza | $134 | $11,64313 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $49 | $4,815358 claims |
| IBSA Pharma Inc.Tirosint | $58 | $4,48711 claims |
| AbbVieSynthroid | $152 | $4,39951 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
Other endocrinology, diabetes & metabolism in Montgomery
- Hima AmmanaMontgomery$9K
- Manisha GargMontgomery$8K
- Warda NiazMontgomery$8K
- Vaishall ThudiMontgomery$8K
- Elaina AdderleyMontgomery$7K
- Mohammad-Ehsan OwrangiMontgomery$3K
- Neil SchaffnerOpelika$642K
- Ralph TeagueBirmingham$487K
- Bantwal BaligaOpelika$483K
- William GarveyBirmingham$421K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.